Suppression of the alveolitis in pulmonary sarcoidosis by oral corticosteroids

Giovanni A. Rossi, Giorgio Bernabò Di Negro, Emma Balzano, Ettore Cerri, Oliviero Sacco, Bruno Balbi, Andrea Venturini, Rossana Ramoino, Cesare Ravazzoni

Research output: Contribution to journalArticlepeer-review


We evaluated the effects of daily prednisone therapy on alveolitis parameters and pulmonary function tests over a six month period in patients with active pulmonary sarcoidosis (>28% T lymphocytes in bronchoalveolar lavage and positive gallium-67 (67Ga) lung scans). 10 patients with biopsyproven lung disease were studied. Analysis of bronchoalveolar lavage cells and of67Ga scanning at the beginning and at the end of the study period demonstrated that prednisone treatment significantly lowered the percentages of T lymphocytes in bronchoalveolar lavage in all patients (baseline 48±3%, after treatment 19±5%, p67Ga lung scans improved in 8 of the 10 patients. Pulmonary function tests showed improvement of the parameters studied (+7.5±2.1% mean change in vital capacity, +4.7±1.6% mean change in total lung capacity, +5.4±2% mean change in forced expiratory volume in one second and +6.2±1.5% mean change in diffusing capacity). In addition none of the treated patients deteriorated functionally and 9 of the 10 patients improved more than 10% in at least one parameter. These results indicate that daily oral prednisone therapy is effective in suppressing the alveolitis in pulmonary sarcoidosis and that it is able to preserve lung functions in patients who, without treatment, would be likely to deteriorate.

Original languageEnglish
Pages (from-to)83-93
Number of pages11
Issue number1
Publication statusPublished - Dec 1985


  • Alveolitis
  • Corticosteroids
  • Sarcoidosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Physiology


Dive into the research topics of 'Suppression of the alveolitis in pulmonary sarcoidosis by oral corticosteroids'. Together they form a unique fingerprint.

Cite this